Forced Expression of ZNF143 Restrains Cancer Cell Growth

We previously reported that the transcription factor Zinc Finger Protein 143 (ZNF143) regulates the expression of genes associated with cell cycle and cell division, and that downregulation of ZNF143 induces cell cycle arrest at G2/M. To assess the function of ZNF143 expression in the cell cycle, we established two cells with forced expression of ZNF143 derived from PC3 prostate cancer cell lines. These cell lines overexpress genes associated with cell cycle and cell division, such as polo-like kinase 1 (PLK1), aurora kinase B (AURKB) and some minichromosome maintenance complex components (MCM). However, the doubling time of cells with forced expression of ZNF143 was approximately twice as long as its control counterpart cell line. Analysis following serum starvation and re-seeding showed that PC3 cells were synchronized at G1 in the cell cycle. Also, ZNF143 expression fluctuated, and was at its lowest level in G2/M. However, PC3 cells with forced expression of ZNF143 synchronized at G2/M, and showed lack of cell cycle-dependent fluctuation of nuclear expression of MCM proteins. Furthermore, G2/M population of both cisplatin-resistant PCDP6 cells over-expressing ZNF143 (derived from PC3 cells) and cells with forced expression of ZNF143 was significantly higher than that of each counterpart, and the doubling time of PCDP6 cells is about 2.5 times longer than that of PC3 cells. These data suggested that fluctuations in ZNF143 expression are required both for gene expression associated with cell cycle and for cell division.

[1]  H. Yin,et al.  An integrative approach to identify YB‐1‐interacting proteins required for cisplatin resistance in MCF7 and MDA‐MB‐231 breast cancer cells , 2011, Cancer science.

[2]  Zili He,et al.  Polo-like kinase 1 contributes to the tumorigenicity of BEL-7402 hepatoma cells via regulation of Survivin expression. , 2011, Cancer letters.

[3]  G. Wood,et al.  Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis , 2011, Cell cycle.

[4]  C. Pirker,et al.  Overexpression of Aurora-A in primary cells interferes with S-phase entry by diminishing Cyclin D1 dependent activities , 2011, Molecular Cancer.

[5]  Y. Sasaguri,et al.  Role of ZNF143 in tumor growth through transcriptional regulation of DNA replication and cell‐cycle‐associated genes , 2010, Cancer science.

[6]  A. Donson,et al.  Inhibition of Aurora Kinase A enhances chemosensitivity of medulloblastoma cell lines , 2010, Pediatric blood & cancer.

[7]  Y. Sasaguri,et al.  Y‐box binding protein‐1 is a novel molecular target for tumor vessels , 2010, Cancer science.

[8]  H. Izumi,et al.  Y-box binding protein-1 (YB-1) promotes cell cycle progression through CDC6-dependent pathway in human cancer cells. , 2010, European journal of cancer.

[9]  H. Izumi,et al.  ZNF143 interacts with p73 and is involved in cisplatin resistance through the transcriptional regulation of DNA repair genes , 2007, Oncogene.

[10]  K. W. Kim,et al.  Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests. , 2007, International journal of radiation oncology, biology, physics.

[11]  P. Carbon,et al.  A Genome Scale Location Analysis of Human Staf/ZNF143-binding Sites Suggests a Widespread Role for Human Staf/ZNF143 in Mammalian Promoters* , 2006, Journal of Biological Chemistry.

[12]  N. Ayad.  CDKs Give Cdc6 a License to Drive into S Phase , 2005, Cell.

[13]  Y. Yoshida,et al.  ZNF143 activates gene expression in response to DNA damage and binds to cisplatin‐modified DNA , 2004, International journal of cancer.

[14]  E. Golemis,et al.  A Novel RING Finger Protein, Human Enhancer of Invasion 10, Alters Mitotic Progression through Regulation of Cyclin B Levels , 2003, Molecular and Cellular Biology.

[15]  P. Carbon,et al.  Structural organization of Staf-DNA complexes. , 2000, Nucleic acids research.

[16]  H. Takano,et al.  Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. , 1999, Cancer research.

[17]  G. Kunkel,et al.  Molecular cloning of a cDNA encoding human SPH-binding factor, a conserved protein that binds to the enhancer-like region of the U6 small nuclear RNA gene promoter. , 1998, Nucleic acids research.

[18]  P. Carbon,et al.  ZNF76 and ZNF143 Are Two Human Homologs of the Transcriptional Activator Staf* , 1998, The Journal of Biological Chemistry.

[19]  N. Copeland,et al.  cDNA cloning, expression, subcellular localization, and chromosomal assignment of mammalian aurora homologues, aurora-related kinase (ARK) 1 and 2. , 1998, Biochemical and biophysical research communications.

[20]  M. Tanimoto,et al.  Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. , 1996, Cancer research.

[21]  H. Izumi,et al.  Twist promotes tumor cell growth through YB-1 expression. , 2008, Cancer research.

[22]  P. Carbon,et al.  Staf, a promiscuous activator for enhanced transcription by RNA polymerases II and III , 1997, The EMBO journal.

[23]  R. Pepperkok,et al.  A human nuclear protein with sequence homology to a family of early S phase proteins is required for entry into S phase and for cell division. , 1994, Journal of cell science.